AUTHORS
Sun Ting, PhD, Fengyu Long2, Liu Aixue3, Chen Yunfei, MD4, Lei Zhang, MD5
AFFILIATIONS
1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
ABSTRACT
Background
Immune thrombocytopenia (ITP) in children and adolescents who fail to achieve adequate responses to first-line therapies, including corticosteroids or intravenous immunoglobulin (IVIG), often requires second-line treatment. Thrombopoietin receptor agonists (TPO-RAs) are recommended as preferred second-line options due to their efficacy and convenience. However, currently available pediatric TPO-RAs have limitations: eltrombopag requires dietary restrictions and monitoring for potential hepatotoxicity, whereas romiplostim requires weekly subcutaneous administration. Avatrombopag, an oral TPO-RA, can be administered without dietary restrictions and has not been associated with clinically significant hepatotoxicity. Although switching between TPO-RAs has shown favorable outcomes in adults, evidence regarding TPO-RA switching strategies in pediatric ITP remains limited. This prospective study evaluated the efficacy and safety of avatrombopag in children and adolescents with ITP who had an inadequate response or intolerance to prior eltrombopag therapy.
Methods
This prospective, single-arm, open-label study (ClinicalTrials.gov identifier: NCT06281327) enrolled 87 pediatric patients with ITP aged 1–17 years who had platelet counts <30 × 10?/L despite prior eltrombopag treatment. All patients were switched to avatrombopag because of insufficient response, platelet count fluctuation, intolerance, treatment preference, or financial considerations. Patients received avatrombopag treatment for 12 weeks.
The primary efficacy endpoint was achievement of platelet response, defined as platelet count ≥30 × 10?/L on at least two consecutive assessments, with a ≥2-fold increase from baseline and absence of active bleeding. Secondary endpoints included the proportion of patients achieving platelet counts ≥50 × 10?/L at Week 8, complete response (CR; platelet count ≥100 × 10?/L) at Week 8, time to response (TTR), bleeding events graded according to World Health Organization (WHO) criteria, and treatment-emergent adverse events (TEAEs).
Results
Among 87 enrolled patients, 74.7% (65/87) achieved the primary efficacy endpoint. The median time to response was 2 weeks. At Week 8, 67.8% (59/87) of patients achieved platelet counts ≥50 × 10?/L, and the CR rate was 42.5% (37/87). Bleeding events of any grade decreased substantially from 79.3% at baseline to 10.3% at Week 12. Treatment-related adverse events were mild, with all events classified as Grade 1 or 2. No thromboembolic events, clinically significant hepatotoxicity, or new safety signals were observed.
Conclusion
Avatrombopag demonstrated rapid platelet recovery, sustained efficacy, and favorable tolerability in children and adolescents with ITP who had inadequate responses or intolerance to eltrombopag. These findings provide clinical evidence supporting avatrombopag as an effective and convenient TPO-RA option, particularly for pediatric patients requiring TPO-RA switching.
DISCLOSURES
Sun Ting, PhD: No relevant conflicts of interest to declare.